An HIV Diagnostic Testing Algorithm Using the cobas HIV-1/HIV-2 Qualitative Assay for HIV Type Differentiation and Confirmation

Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) diagnostic testing algorithms recommended by the Centers for Disease Control involve up to three tests and rely mostly on detection of viral antigen and host antibody responses. HIV-1 p24 antigen/HIV-1/HIV-2 antibody-reactive specimens are confirmed with an immunochromatographic HIV-1/HIV-2 antibody differentiation assay, and negative or indeterminate results from the differentiation assay are resolved by an HIV-1-specific nucleic acid amplification test (NAT). ABSTRACT Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) diagnostic testing algorithms recommended by the Centers for Disease Control involve up to three tests and rely mostly on detection of viral antigen and host antibody responses. HIV-1 p24 antigen/HIV-1/HIV-2 antibody-reactive specimens are confirmed with an immunochromatographic HIV-1/HIV-2 antibody differentiation assay, and negative or indeterminate results from the differentiation assay are resolved by an HIV-1-specific nucleic acid amplification test (NAT). The performance of a proposed alternative algorithm using the cobas HIV-1/HIV-2 qualitative NAT as the differentiation assay was evaluated in subjects known to be infected with HIV-1 (n = 876) or HIV-2 (n = 139), at low (n = 6,017) or high (n = 1,020) risk of HIV-1 infection, or at high-risk for HIV-2 infection (n = 498) (study A). The performance of the cobas HIV-1/HIV-2 qualitative test was also evaluated by comparison to an HIV-1 or HIV-2 alternative NAT (study B). The HIV-1 and HIV-2 overall percent agreements (OPA) in study A ranged from 95% to 100% in all groups. The positive percent agreements (PPA) for HIV-1 and HIV-2 were 100% (876/876) and 99.4% (167/168), respectively, for known positive groups. The negative percent agreement in the HIV low-risk group was 100% for both HIV-1 and HIV-2. In study B, the HIV-1 and HIV-2 OPA ranged from 99% to 100% in all groups evaluated (n = 183 to 1,030), and the PPA for HIV-1 and HIV-2 were 100% and 99.5%, respectively, for known positive groups. The cobas HIV-1/HIV-2 qualitative assay can discriminate between HIV-1 and HIV-2 based on HIV RNA and can be included in an alternative diagnostic algorithm for HIV.

[1]  Y. Wang,et al.  Routine HIV Test Results in 6 US Clinical Laboratories Using the Recommended Laboratory HIV Testing Algorithm With Geenius HIV 1/2 Supplemental Assay. , 2020, Sexually transmitted diseases.

[2]  J. Brooks,et al.  Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test — United States, 2010–2017 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  S. Owen,et al.  Could HIV-1 RNA be an option as the second step in the HIV diagnostic algorithm? , 2020, Sexually transmitted diseases.

[4]  Shilpa N. Patel,et al.  Performance of an Alternative Laboratory-Based HIV Diagnostic Testing Algorithm Using HIV-1 RNA Viral Load. , 2019, Sexually transmitted diseases.

[5]  C. Tremblay,et al.  Evaluation of the Bio-Rad Geenius HIV 1/2 Assay as Part of a Confirmatory HIV Testing Strategy for Quebec, Canada: Comparison with Western Blot and Inno-Lia Assays , 2019, Journal of Clinical Microbiology.

[6]  P. Peters,et al.  Performance evaluation of the Bio-Rad Geenius HIV 1/2 supplemental assay. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  G. Gottlieb,et al.  90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. , 2018, The lancet. HIV.

[8]  Jeffrey N. Martin,et al.  Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms , 2017, Journal of acquired immune deficiency syndromes.

[9]  J. Baeten,et al.  The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion , 2017, AIDS.

[10]  H. Zinszner,et al.  HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. , 2015, Vaccine.

[11]  M. Delforge,et al.  Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  M. Pentella,et al.  Laboratory testing for the diagnosis of HIV infection : updated recommendations , 2014 .

[13]  J. Albert,et al.  Evaluation of Bio-Rad Geenius HIV-1 and -2 Assay as a Confirmatory Assay for Detection of HIV-1 and -2 Antibodies , 2014, Clinical and Vaccine Immunology.

[14]  O. Tarasenko,et al.  2014 European Guideline on HIV testing , 2014, International journal of STD & AIDS.

[15]  M. Pandori,et al.  Suggested reporting language for the HIV laboratory diagnostic testing algorithm , 2013 .

[16]  G. Gottlieb,et al.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  S. Bowden,et al.  Stability of Hepatitis C Virus, HIV, and Hepatitis B Virus Nucleic Acids in Plasma Samples after Long-Term Storage at −20oC and −70oC , 2011, Journal of Clinical Microbiology.

[18]  O. Lambotte,et al.  Epidemiology and clinical characteristics of elite controllers , 2011, Current opinion in HIV and AIDS.

[19]  R. Gandhi,et al.  Update on human immunodeficiency virus (HIV)-2 infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  V. Calvez,et al.  Stability of HIV RNA in plasma specimens stored at different temperatures , 2008, HIV medicine.

[21]  V. Calvez,et al.  Evaluation of the use of dried spots and of different storage conditions of plasma for HIV‐1 RNA quantification , 2007, HIV medicine.

[22]  J. Schapiro,et al.  Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv , 2004, Antiviral therapy.

[23]  Joseph P. Romano,et al.  Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma , 1997, Journal of clinical microbiology.